HBV Assets

Pursuing a cure for Chronic Hepatitis B (cHBV).

Chronic Hepatitis B (cHBV) is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). Persons chronically infected with HBV are at increased risk of developing significant liver disease, including cirrhosis, or permanent scarring of the liver, as well as liver failure and hepatocellular carcinoma (HCC). Given the widespread prevalence of cHBV infections and the shortcomings of existing treatment regimens, we believe there is a compelling market opportunity for an HBV curative regimen.

Seeking Cure Chronic Hepatatis B

HBV by the Numbers

290
million people

suffer from cHBV worldwide.

2.4
million people

suffer from cHBV in the United States.

820
thousand mortalities

occur due to cHBV related complications each year.

Chbv Illustration Liver

Coronovirus

Lifelong therapeutics, and the hope for more.

Today’s current treatment options for cHBV include pegylated interferon-α (Peg-IFNα) and nucleos(t)ide analogues (NAs). However, in most cases, once Peg-IFNα and NA therapies are stopped, virus replication resumes, and liver inflammation and fibrosis may still progress. While these treatments reduce viral load, less than 5% of patients are functionally cured (defined as sustained HBV DNA suppression and HBsAg loss that is maintained >6 months after discontinuation of all antiviral therapy) after a variable and usually prolonged treatment duration. With such low cure rates, most patients with cHBV are required to take NA therapy daily for the rest of their lives.

Despite these treatment options, there remains an unmet medical need for novel, finite, and more efficacious cHBV treatments that result in improved long-term outcomes, including an increased chance for functional cure.

Pursuing a cure for HBV through multiple, complementary mechanisms.

Recognizing that monotherapy approaches are unlikely to be successful in promoting functional cure in patients with cHBV, we are taking a three-pronged approach that combines compounds with complementary mechanisms of action to suppress viral DNA, reduce viral antigens and boost the host immune system.

Our lead asset, AB-729, an RNAi therapeutic, is being developed as the cornerstone in a combination treatment strategy that includes NA therapy and potentially any of our proprietary compounds AB-836 (capsid inhibitor), AB-101 (PD-L1 inhibitor), and AB-161 (RNA destabilizer), and/or Peg-IFNα, and other compounds in development or approved.

Here’s how it works.

Icon Suppress Viral Dna

Suppress viral DNA

Block replication via NA, RNAi, RNA destabilizer, and/or capsid inhibitor.

Icon Reduce Viral Antigens

Reduce viral antigens

Block HBsAg via RNAi and RNA destabilizer.

Icon Boost Immune Response

Boost immune response

Induce immune modulation via PD-L1 inhibitor, interferon, therapeutic vaccines, RNAi and/or RNA destabilizer.

3-Pronged Approach to Therapeutic Success

3 Prong Approach To Therapeutic Success
Pipeline Cta

Pipeline

Explore our pipeline of clinical and preclinical studies.

Check out our pipeline

Pan Coronavirus Treatment

Coronavirus

Learn more about how we are innovating in pan-coronavirus treatment.

Discover our coronavirus assets